SCHEMBL6322345

SCHEMBL6322345

COc1cccc(-c2cccc3c2C(=Cc2[nH]cc(C(=O)N4C[C@@H](C)N[C@@H](C)C4)c2C)C(=O)N3)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 11/20 0.46
KDR P35968 10/20 0.46
FGFR1 P11362 10/20 0.46
EGFR P00533 6/20 0.46
AURKA O14965 1/20 0.41
KIT P10721 1/20 0.41
PDGFRA P16234 1/20 0.41
FLT4 P35916 1/20 0.41
FLT3 P36888 1/20 0.41
AURKB Q96GD4 1/20 0.41
PDPK1 O15530 1/20 0.38
AKT2 P31751 1/20 0.38
TGM2 P21980 1/20 0.36
SRC P12931 1/20 0.36
ZAP70 P43403 1/20 0.36
CDK2 P24941 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322341 1.00 PDGFRB (0.46) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6329374 1.00 PDGFRB (0.46) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6329388 1.00 PDGFRB (0.46) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6329373 1.00 PDGFRB (0.46) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6322348 1.00 PDGFRB (0.46) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6321687 0.92 KDR (0.44) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6763372 0.92 KDR (0.44) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6321681 0.92 KDR (0.44) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6763374 0.92 KDR (0.44) PDGFRBKDRFGFR1EGFRAURKA
SCHEMBL6319380 0.92 KDR (0.44) PDGFRBKDRFGFR1EGFRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 PDGFRB 575/4885KDR 819/4885FGFR1 525/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 PDGFRB 575/4885KDR 819/4885FGFR1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.